Vyome secures exclusive license from Impetis for selective JAK inhibitor programs

The global JAK inhibitors market is projected to REACH $56.78 billion by 2030, reflecting strong demand for targeted immunology treatments

Bristol Myers Squibb wins EU nod for Sotyktu in active psoriatic arthritis

The once-daily oral therapy is the first and only tyrosine kinase 2 (TYK2) inhibitor approved in the European Union for this indication, marking a significant expansion of its immunology portfolio

FUJIFILM Biosciences & NextCell launch platform to standardize regenerative medicine development

The move targets long-standing bottlenecks in MSC science, including cell-to-cell variability, immunocompatibility concerns, and inefficient manufacturing workflows

Experts push for patient-centric healthcare at IHW Patient First Summit 2026

Healthcare leaders, policymakers, hospitals, and patient advocates discuss AI-driven healthcare, digital transformation, quality of life in cancer care

ICMR launches fellowship programme for biomedical scientists from developing countries

Initiative aims to strengthen South-South collaboration and capacity building in biomedical research

China poised to launch world’s first CAR-T therapy for gastric cancer

As per GlobalData, CARsgen’s satri-cel could mark a major breakthrough in solid tumor treatment as competition intensifies

ADMA Biologics wins FDA nod to expand ASCENIV use in young children

Lilly’s Omvoh shows rare long-term remission milestone in ulcerative colitis

Samsung Bioepis’ Pembrolizumab biosimilar SB27 meets phase 1 PK endpoints

The proposed biosimilar to Keytruda demonstrated pharmacokinetic bioequivalence in a multicountry Phase 1 study involving non-small cell lung cancer patients

Swiss Biotech Association reports CHF 7.5 billion revenue for Switzerland’s biotech Industry in 2025

The private funding rose 38% amid growing international collaborations and CDMO demand